Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Memphasys Ltd ( (AU:MEM) ) just unveiled an announcement.
Memphasys Limited has completed the placement of 193,055,540 shortfall shares at $0.003 each, together with 48,263,886 free attaching unlisted options, raising $579,166.62 and bringing total proceeds from its recent entitlement offer to about $1.12 million. The funds will be used to accelerate commercial rollout of the Felix System in Europe following CE Mark approval, expand sales efforts in the Middle East and North Africa, support early demand through inventory and manufacturing scale-up, fast-track regulatory approvals in Australia and India, and bolster working capital, moves the board says are intended to underpin near-term revenue generation and scalable growth for the fertility technology specialist.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
More about Memphasys Ltd
Memphasys Limited is an Australian-based reproductive biotechnology company focused on commercialising the Felix System, a patented bioseparation technology used to isolate the most viable sperm cells for human assisted reproduction. By combining electrophoresis and size-exclusion membranes, Felix aims to replace traditional centrifugation with a faster, gentler and more standardised sperm selection process, and the company’s commercial strategy targets contracted sales through direct and distribution channels, scaled production and positioning Felix as a new global standard in sperm preparation for assisted reproductive technology procedures.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$13.07M
Find detailed analytics on MEM stock on TipRanks’ Stock Analysis page.